Back to List View Graph View

Nirsevimab

Nirsevimab is a long-acting monoclonal antibody used for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants.

Where the papers sit

20 papers from the last 6 months study nirsevimab directly · updated from PubMed 13 Nov 2026

Study type 0 clinical trials · 13 observational · 7 human data

Themes one subject · 1 new direction

Those 20 are all about one subject.

  • Infant RSV Prevention

    Infant RSV prevention is moving from efficacy evidence toward population-wide implementation and strategy optimization. Real-world studies focus on hospitalization reduction, bronchiolitis, acute otitis media, protection duration and safety, while regional effects remain heterogeneous. Nirsevimab is increasingly compared with maternal RSVpreF vaccination, seasonal versus year-round schedules, and combined programmes. Uptake, parental and clinician acceptance, cost-effectiveness and protection of high-risk infants remain central to policy decisions.

    20 papers

NEW DIRECTION

Nirsevimab becomes an object of evolutionary resistance surveillance, not only an infant-prevention intervention

The French multicentre study of RSV-B breakthrough infections examines nirsevimab escape using genotypic and phenotypic methods rather than evaluating nirsevimab primarily as an infant-prevention product. It identifies breakthrough RSV-B infection and possible resistance emergence as the central problem, extending nirsevimab’s role to the surveillance of antibody escape and the durability of its conserved prefusion-F target 42229496Jun.

Papers

The 20 papers from the last 6 months that study nirsevimab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Infant RSV Prevention (20)
  1. RSV bronchiolitis admissions in infants immunized with nirsevimab: a multicenter observational study. European journal of pediatrics · 12 Nov 2026 PMID 43018749
  2. Nirsevimab reduced acute otitis media infections in infants-a nationwide interrupted time-series analysis. European journal of pediatrics · 9 Oct 2026 PMID 42855657
  3. Safety of nirsevimab in children aged 0-24 months: Analysis based on EudraVigilance data (2023-2025). Human vaccines & immunotherapeutics · 9 Oct 2026 PMID 42851207
  4. Heterogeneous reduction in pediatrics RSV hospitalizations following regional nirsevimab immunization strategies: a multicenter study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 27 Aug 2026 PMID 42660409
  5. Comparing the potential impacts of seasonal immunisation against year-round immunisation to prevent RSV infant hospitalisations in Japan: A modelling study. Vaccine · 26 Aug 2026 PMID 42648051
  6. Pediatricians' attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey. PloS one · 17 Aug 2026 PMID 42607062
  7. Effectiveness of nirsevimab and maternal RSVpreF vaccination against infant hospitalization across the island of Ireland. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 6 Aug 2026 PMID 42562126
  8. Effectiveness of RSV Prevention Strategies in US Infants: 2024-2025. Pediatrics · 3 Aug 2026 PMID 42547085
  9. Cost-benefit analysis of nirsevimab for respiratory syncytial virus prevention in infants: a population-based study. European journal of pediatrics · 3 Jul 2026 PMID 42399582
  10. Respiratory syncytial virus outcomes and duration of protection following nirsevimab administration in high-risk infants: a real-world study under year-round epidemic circulation in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 23 Jun 2026 PMID 42336142
  11. Cost-effectiveness and public health impact of RSV immunization for all infants in Japan: a mixed strategy with nirsevimab and RSVpreF. Expert review of vaccines · 23 Jun 2026 PMID 42334170
  12. Uptake and predictors of newborn respiratory syncytial virus (RSV) immunisation with nirsevimab in Ireland's national pilot programme: a cross-sectional study. BMJ open · 22 Jun 2026 PMID 42331576
  13. Acceptance of the respiratory syncytial virus infant monoclonal antibody nirsevimab among post-partum women in Italy. Human vaccines & immunotherapeutics · 10 Jun 2026 PMID 42268596
  14. Economic evaluation of a bivalent respiratory syncytial virus prefusion F vaccine for maternal vaccination in Sweden: cost-effectiveness and budget impact. Journal of medical economics · 8 Jun 2026 PMID 42258348
  15. Acceptability and preferences regarding RSV immunisation during pregnancy: a cross-sectional study in diverse global settings. Vaccine · 7 Jun 2026 PMID 42251842
  16. What is the Optimal RSV Immunization Strategy for Infants Born in the RSV Off-season? The Journal of infectious diseases · 5 Jun 2026 PMID 42246569
  17. Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France. The Lancet. Microbe · 2 Jun 2026 PMID 42229496
  18. First year of nirsevimab use in Argentina (2025): Report from a private vaccination center. Archivos argentinos de pediatria · 26 May 2026 PMID 42189590
  19. Infant respiratory syncytial virus (RSV) immunisation coverage in an Australian regional area, 1 May 2024 - 31 October 2025. Communicable diseases intelligence (2018) · 25 May 2026 PMID 42184438
  20. Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia. Vaccine · 23 May 2026 PMID 42176437

By study type

Observational studies and case reports (13)
  1. RSV bronchiolitis admissions in infants immunized with nirsevimab: a multicenter observational study. European journal of pediatrics · 12 Nov 2026 PMID 43018749
  2. Nirsevimab reduced acute otitis media infections in infants-a nationwide interrupted time-series analysis. European journal of pediatrics · 9 Oct 2026 PMID 42855657
  3. Heterogeneous reduction in pediatrics RSV hospitalizations following regional nirsevimab immunization strategies: a multicenter study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 27 Aug 2026 PMID 42660409
  4. Pediatricians' attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey. PloS one · 17 Aug 2026 PMID 42607062
  5. Effectiveness of nirsevimab and maternal RSVpreF vaccination against infant hospitalization across the island of Ireland. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 6 Aug 2026 PMID 42562126
  6. Cost-benefit analysis of nirsevimab for respiratory syncytial virus prevention in infants: a population-based study. European journal of pediatrics · 3 Jul 2026 PMID 42399582
  7. Respiratory syncytial virus outcomes and duration of protection following nirsevimab administration in high-risk infants: a real-world study under year-round epidemic circulation in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 23 Jun 2026 PMID 42336142
  8. Cost-effectiveness and public health impact of RSV immunization for all infants in Japan: a mixed strategy with nirsevimab and RSVpreF. Expert review of vaccines · 23 Jun 2026 PMID 42334170
  9. Uptake and predictors of newborn respiratory syncytial virus (RSV) immunisation with nirsevimab in Ireland's national pilot programme: a cross-sectional study. BMJ open · 22 Jun 2026 PMID 42331576
  10. Acceptance of the respiratory syncytial virus infant monoclonal antibody nirsevimab among post-partum women in Italy. Human vaccines & immunotherapeutics · 10 Jun 2026 PMID 42268596
  11. Acceptability and preferences regarding RSV immunisation during pregnancy: a cross-sectional study in diverse global settings. Vaccine · 7 Jun 2026 PMID 42251842
  12. Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France. The Lancet. Microbe · 2 Jun 2026 PMID 42229496
  13. Infant respiratory syncytial virus (RSV) immunisation coverage in an Australian regional area, 1 May 2024 - 31 October 2025. Communicable diseases intelligence (2018) · 25 May 2026 PMID 42184438
Human data, design not indexed (7)
  1. Safety of nirsevimab in children aged 0-24 months: Analysis based on EudraVigilance data (2023-2025). Human vaccines & immunotherapeutics · 9 Oct 2026 PMID 42851207
  2. Comparing the potential impacts of seasonal immunisation against year-round immunisation to prevent RSV infant hospitalisations in Japan: A modelling study. Vaccine · 26 Aug 2026 PMID 42648051
  3. Effectiveness of RSV Prevention Strategies in US Infants: 2024-2025. Pediatrics · 3 Aug 2026 PMID 42547085
  4. Economic evaluation of a bivalent respiratory syncytial virus prefusion F vaccine for maternal vaccination in Sweden: cost-effectiveness and budget impact. Journal of medical economics · 8 Jun 2026 PMID 42258348
  5. What is the Optimal RSV Immunization Strategy for Infants Born in the RSV Off-season? The Journal of infectious diseases · 5 Jun 2026 PMID 42246569
  6. First year of nirsevimab use in Argentina (2025): Report from a private vaccination center. Archivos argentinos de pediatria · 26 May 2026 PMID 42189590
  7. Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia. Vaccine · 23 May 2026 PMID 42176437